Form 4: Arcus Biosciences President Jaen Juan C. Reports Stock and Option Grants

Arcus Biosciences' President, Jaen Juan C., reports the acquisition of restricted stock units and stock options, along with adjustments to existing holdings.

Summary

• On January 23, 2025, Jaen Juan C., President of Arcus Biosciences, reported transactions involving the company's stock.
• Jaen Juan C. was granted 50,000 shares of common stock in the form of restricted stock units.
• These restricted stock units vest in four equal annual installments starting December 15, 2025, contingent upon continued service to the company.
• Jaen Juan C. also received an option to purchase 200,000 shares of common stock at an exercise price of $13.33.
• The option becomes exercisable in 48 equal monthly installments beginning January 1, 2025, also subject to continued service.
• Following these transactions, Jaen Juan C. directly owns 367,220 shares of common stock and indirectly owns 1,188,233 shares through a trust.
• Jaen Juan C. also directly holds options for 200,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reports standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholder value. There are no indications of negative events or concerns.

Positives

• The grant of restricted stock units and stock options to the President aligns his interests with the long-term success of the company.
• The vesting schedules for both the restricted stock units and stock options incentivize continued service to Arcus Biosciences.

Future Outlook

The reported transactions suggest continued alignment of management's interests with the company's performance through equity-based compensation.

Industry Context

Stock grants and options are common forms of executive compensation in the biotechnology industry, aligning management incentives with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Arcus Biosciences.
• Companies such as Gilead Sciences and Amgen also utilize stock options and restricted stock units to incentivize their leadership teams.
• The vesting schedules described are typical for executive compensation packages, designed to retain key personnel over several years.

Stakeholder Impact

• Shareholders may view the stock and option grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates